Clinical trial · no report yet · Phase 1
DeLLphi-303
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- NCT05361395 ↗
- Active, not recruiting
- Amgen
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 49 | |
| Podcasts | 23 | |
| YouTube | 22 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung (DeLLphi-303)
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- Tarlatamab; Carboplatin; Etoposide; Atezolizumab; Durvalumab
- Arms
- Part 1: Dose Exploration Combination Regimen 1 · Experimental
- Part 2: Dose Exploration Combination Regimen 2 · Experimental
- Part 3: Dose Exploration Combination Regimen 3 · Experimental
- Part 4: Dose Expansion · Experimental
- Part 5: Dose Exploration Maintenance · Experimental
- Part 6: Dose Expansion Maintenance · Experimental
- Part 7: Dose Expansion · Experimental
- Part 8: Dose Expansion Maintenance · Experimental
- Part 9: Dose Expansion Maintenance · Experimental
- Enrollment
- 184
- Primary outcomes
- Number of Participants with a Dose Limiting Toxicity (DLT)
- Number of Participants with Treatment-emergent Adverse Events (TEAE)
- Number of Participants with Treatment-related Adverse Events
- Number of Participants with Clinically Significant Changes in Vital Signs
- Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Measurements
- Number of Participants with Clinically Significant Changes in Clinical Laboratory Tests
- Sponsor
- Amgen
- Start
- Aug 24, 2022
- Primary completion
- May 30, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT05361395 · updated Sep 9, 2026
Publications
linked from the registry- Paulson KG, Lau SCM, Ahn MJ, Moskovitz M, Pogorzelski M, Hafliger S, Parkes A, Zhang Y, Hamidi A, Thompson CG, Wermke M. Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study. Lancet Oncol. 2025 Oct;26(10):1300-1311. doi: 10.1016/S1470-2045(25)00480-2. Epub 2025 Sep 8. PubMed 40934933